Close Menu

NEW YORK (GenomeWeb) – Danaher announced after the close of the market on Monday concurrent offerings of its common stock and its mandatory convertible preferred stock to fund, in part, its proposed $21.4 billion acquisition of GE's Biopharma business.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.